DLL4

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Biopsy, NSCLC, Entrepreneurship, Carcinoma, DLL4, Patient, Neoplasm, PET, Merck, G&A, Doctor of Philosophy, MD, Insurance, IND, Mesothelioma, Research and development, CD137, Therapy, Paclitaxel, BTC, CRC, Melanoma, Stage 2, PD-L1, FDA, SCLC, PD-1, Pharmaceutical industry

Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.

Key Points: 
  • Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.
  • The increase was primarily attributable to higher stock compensation expense of $1.0 million offset by lower insurance costs of $0.3 million.
  • During 2023, the Company decreased its cash position by $34.1 million, primarily from $40.6 million of net cash used in operating activities.

ACROBiosystems Launches New Initiative to Support Cell and Gene Manufacturers

Retrieved on: 
Monday, March 4, 2024
Senior, Interview, DLL4, GMP, Research, Pharmaceutical industry

NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of innovative cell and gene therapies.

Key Points: 
  • NEWARK, Calif., March 4, 2024 /PRNewswire/ -- ACROBiosystems, one of the leading providers of innovative tools and solutions used from discovery to the clinic, has announced a new corporate initiative to support ex vivo cell manufacturing and manufacturers of innovative cell and gene therapies.
  • In response to the shifting landscape of biologics manufacturing across the globe, this initiative is designed to be the leading point of ACROBiosystems' new mission of "overcoming challenges from discovery to the clinic with innovation".
  • With the launch of this initiative, ACROBiosystems seeks to stratify its products under a cell therapy modality-oriented perspective, streamlining the transition from research to the clinic by offering progressive reagents at each stage.
  • By empowering scientists and engineers engaged in cell therapy manufacturing, ACROBiosystems seeks to help simplify and accelerate the development of new, better, and more affordable medicines.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024
Patient, CRC, Stage 2, IND, FDA, BTC, Research and development, PD-1, DLL4, CD137, PET, Melanoma, MD, Doctor of Philosophy, Therapy, Mesothelioma, Paclitaxel, Carcinoma, SCLC, Safety, Development, NSCLC, PD-L1, Pharmaceutical industry

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

ACROBiosystems launches GM-grade DLL4 Protein to accelerate stem cell manufacturing

Retrieved on: 
Thursday, November 16, 2023
Mycoplasma, IND, Uncertainty, Fibroblast, Growth, B cell, Risk, DLL4, Research, Safety, GMP, Virus, A-DNA, Quality assurance, Vaccine

The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.

Key Points: 
  • The availability of DLL4 manufactured under GMP conditions represents a significant milestone for enterprises engaged in developing or manufacturing stem-cell based biologics.
  • The GMP process guarantees that the DLL4 recombinant protein is consistent, contaminant-free, and developed in a controlled production environment for use as a raw material in stem cell culturing.
  • Conventionally, feeder cells such as OP9-DLL4 are employed to secrete DLL4 during the growth and differentiation of stem cells in vitro.
  • As such, these feeder cells are often utilized to stem cell research and develop potential therapies.

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Bispecific monoclonal antibody, Patient, FDA, PD-L1, Trial of the century, IND, Therapy, Paclitaxel, G&A, AUC, PD-1, Doctor of Philosophy, Entrepreneurship, Stage 2, Development, CRC, Key Stage 1, Research and development, DLL4, Safety, Management, Fine chemical, Nursing, Pharmaceutical industry, Cryptocurrency, Research, Compass, MD, BTC

Transition to take place on January 9th 2024

Key Points: 
  • Transition to take place on January 9th 2024
    Ended the third quarter with $164 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.
  • During the first nine months of 2023, the Company used $28 million of cash to fund operations.
  • R&D expenses were $8.8 million for the quarter ended September 30, 2023, as compared to $9.8 million for the same period in 2022, a decrease of approximately $1.0 million or 10%.
  • G&A expenses were $3.1 million for the quarter ended September 30, 2023, as compared to $2.8 million for the same period in 2022, an increase of $0.3 million or 10%.

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Therapy, CRC, G&A, DLL4, Doctor of Philosophy, Trial of the century, Stage 2, Key Stage 1, Patient, Compass, Paclitaxel, Entrepreneurship, BTC, IND, Safety, Nursing, Pharmaceutical industry, Cryptocurrency, MD

Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024

Key Points: 
  • Phase 2 study of CTX-009 in patients with advanced biliary tract cancers (BTC); top line data from this study is now expected in the second half of 2024
    Ended the second quarter with $169 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported second quarter, and year-to-date, 2023 financial results.
  • During the first half of 2023, the Company used $22 million of cash to fund operations.
  • R&D expenses were $10.2 million for the quarter ended June 30, 2023, as compared to $5.9 million for the same period in 2022, an increase of approximately $4.4 million or 74%.
  • G&A expenses were $3.1 million for the quarter ended June 30, 2023 and 2022.

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Kansai Medical University, University, Therapy, Senior, CRC, CFO, Cholangiocarcinoma, EVP, Macrogen, Emergent, G&A, MBA, Dartmouth College, DLL4, Doctor of Philosophy, Arbutus Biopharma, Audit committee, Eli Lilly, Stage 2, Key Stage 1, Margetuximab, Patient, M.B.A, Sprint Corporation, Compass, Cancer, Paclitaxel, CEB, Entrepreneurship, Merck, BTC, Treasurer, R, SVP, Pembrolizumab, Safety, NYSE, HCC, BA, Certified Treasury Professional, Nursing, Management, Pharmaceutical industry, Medical device, MD

Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).

Key Points: 
  • Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC).
  • Initial data expected in the third quarter of 2023
    Expanded the management team with the appointment of Minori Rosales, M.D.
  • Initial results from this study are expected in the third quarter of 2023
    In April 2023, the company appointed Minori Rosales, MD PhD, as Senior Vice President & Head of Clinical Development.
  • Prior to Emergent BioSolutions, from 2009-2017, Mr. Lindahl was Chief Financial Officer at CEB, a NYSE-listed technology company.

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Retrieved on: 
Thursday, December 15, 2022
DLL4, Republic, BTC, Neoplasm, Tumor microenvironment, CRC, Cholangiocarcinoma, ASCO, Seoul National University Hospital, Immune system, Society, Paclitaxel, Compass, Therapy, VEGF, Patient, Pharmaceutical industry, Medical imaging

Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC).

Key Points: 
  • Additional poster presentations by Compass include trials in progress posters for the ongoing Phase 2/3 study of CTX-009 combined with paclitaxel in patients with biliary tract cancers (BTC) and the ongoing Phase 2 study of CTX-009 in patients with metastatic colorectal cancer (CRC).
  • Title: CTX-009 (ABL001), a bispecific antibody targeting DLL4 and VEGF A, in combination with paclitaxel in patients with advanced biliary tract cancer (BTC): A Phase 2 study.
  • Title: Trial in progress: A phase 2 study of CTX-009 in adult patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.

OncXerna Therapeutics Doses First Patient in Phase 2 Trial Evaluating Navicixizumab Alone or in Combination with Chemotherapy in Patients with Select Advanced Solid Tumors

Retrieved on: 
Thursday, September 8, 2022
Neoplasm, Patient, Breast cancer, RNA, Safety, Tumor microenvironment, Fallopian tube cancer, Therapy, Associate, Bevacizumab, Precision medicine, Ovarian cancer, TME, Colorectal cancer, Irinotecan, VEGF, Food, LinkedIn, Prognosis, NYU Langone Health, Fast Track, Bavituximab, GLOBE, Progression-free survival, DLL4, Paclitaxel, Twitter, Oncology, Biomarker, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Medical imaging, Vaccine, Medicine

WALTHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient responses to its targeted oncology therapeutic candidates, today announced the initiation of dosing in a Phase 2 basket trial evaluating the anti-DLL4/VEGF bispecific antibody navicixizumab, alone or in combination with chemotherapy, in patients with select advanced solid tumors.

Key Points: 
  • The colorectal cancer cohort is evaluating navicixizumab alone and in combination with irinotecan, while the triple negative breast cancer cohort is evaluating navicixizumab alone and in combination with paclitaxel.
  • The relationship between TME subtypes and the anti-tumor activity of studied regimens will be evaluated as a secondary endpoint in the trial.
  • Aberrant Notch expression is associated with poor prognosis and treatment resistance in many solid tumors, including colorectal cancer and triple-negative breast cancer.
  • OncXerna Therapeutics is a clinical stage precision medicine oncology company developing novel therapies to treat solid tumors.